← Back to patent-cliff list
EXV-801/Dextromethorphan Hydrobromide
Tier C — Watch / tradeEXV-801/Dextromethorphan Hydrobromide
Exciva GmbH
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：NMDAR
Brand：Deraphan
Indications (approved)：Alzheimer's disease
Regional status
US
Phase III
2026-02-02
EU
Phase III
2026-02-02
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of EXV-801/Dextromethorphan Hydrobromide?
Approved indications include: Alzheimer's disease.
When does the EXV-801/Dextromethorphan Hydrobromide patent expire?
No public expiry year is available for EXV-801/Dextromethorphan Hydrobromide yet; this page updates once verified.
How do I get a quote for EXV-801/Dextromethorphan Hydrobromide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29